Natalie I. U. Vokes, MD

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss ongoing research shaping EGFR-mutated NSCLC care.

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss resistance mechanisms in EGFR-mutated NSCLC.

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss clinical experience with antibody-drug conjugates in EGFR-mutated NSCLC.

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss remaining evidence gaps in EGFR-mutated NSCLC care.

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss risk factors guiding frontline therapy decisions in EGFR-mutated NSCLC.

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss sequencing strategies in advanced EGFR-mutated NSCLC.

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss evolving frontline treatment options in EGFR-mutated non–small cell lung cancer.

Natalie Vokes, MD, discusses emerging biomarkers in non–small cell lung cancer, specifically highlighting the promise of HER3-targeted therapy.

Natalie I. U. Vokes, MD, discusses investigative biomarkers of response to checkpoint inhibitors in the field of oncology.